Advertisement

Der Nervenarzt

, Volume 89, Issue 10, pp 1156–1164 | Cite as

Häufige neurologische Erkrankungen assoziiert mit dem Restless-legs-Syndrom

  • M. Bartl
  • J. Winkelmann
  • B. Högl
  • W. Paulus
  • C. Trenkwalder
Übersichten
  • 485 Downloads

Zusammenfassung

Hintergrund

Das Restless-legs-Syndrom (RLS) ist ein häufiges neurologisches Krankheitsbild. Studien zeigten, dass es mit internistischen und neurologischen Erkrankungen assoziiert auftritt.

Ziele

Anhand dreier assoziierter neurologischer Erkrankungen soll die Bedeutung des RLS für die neurologische Versorgung beurteilt werden.

Material und Methoden

Mittels systematischer Recherche in PubMed hinsichtlich sämtlicher Studien zum RLS in Kombination mit Polyneuropathien (PNP), der Parkinson-Erkrankung (PD) und Multipler Sklerose (MS) erfolgte eine Einordnung nach Methodik und Aufbau in hohe, mittlere oder geringe Studienqualität.

Ergebnisse

Von 16 Studien zum RLS und MS wurden 10 als „hoch“ eingestuft. Die hohe Assoziationsbreite zwischen 13,3 bis zu 65,1 % aufgrund unterschiedlicher Methodik verhindert trotz der eindeutig erhöhten Prävalenz eine zusammenfassende Aussage. Bei 30 Studien zum idiopathischen Parkinson-Syndrom wurden 17 mit hoher Qualität gefunden. Das RLS tritt mit dem idiopathischen Parkinson-Syndrom nur unter Therapie gehäuft auf und hier proportional zur Dauer der dopaminergen Behandlung. Von 24 Studien zu PNP wurden nur 5 als „hoch“ eingestuft, eine erhöhte RLS-Prävalenz wurde für die erworbene PNP nachgewiesen mit heterogener Datenlage für hereditäre Formen.

Schlussfolgerung

Für die diskutierten Erkrankungen besteht eine erhöhte Prävalenz für eine Assoziation mit RLS, die möglicherweise pathophysiologisch durch die Erkrankungen bestimmt wird. Aber auch hier liegen möglicherweise genetische Prädispositionen vor, die in Zukunft hoffentlich genauer klassifiziert werden können.

Schlüsselwörter

Differenzialdiagnose Komorbidität Multiple Sklerose Parkinson Polyneuropathie 

Frequent neurological diseases associated with the restless legs syndrome

Abstract

Background

Restless legs syndrome (RLS) is a common neurological disease. Studies have shown that RLS is associated with a variety of medical and neurological disorders.

Objectives

Using the example of three associated neurological diseases, the significance for everyday therapy decisions is assessed.

Material and methods

A systematic search was carried out in PubMed for all studies with the keyword “RLS” in combination with polyneuropathies (PNP), Parkinson’s disease (PD) and multiple sclerosis (MS) and classified according to the methodology in high, medium or low study quality.

Results

Of 16 studies on RLS and MS, 10 were rated as “high”. The high association frequency of RLS in MS between 13.3% and 65.1% (the variability possibly originates from different methods) prevents further statements about the prevalence. Within 30 studies on Parkinson’s disease 17 were classified as having a high quality. In patients with Parkinson disease RLS occurs most frequently during therapy and is related to the duration of dopaminergic treatment. In patients with polyneuropathy, only 5 out of 24 studies were classified as being of high quality and an increased RLS prevalence was detected for acquired polyneuropathies with heterogeneous data for hereditary forms.

Conclusion

There is an increased prevalence of association with RLS for the diseases discussed. This prevalence is possibly determined by the pathophysiology of these disorders. These diseases are possibly characterized by genetic predispositions as well, which can hopefully be classified more accurately in the future.

Keywords

Differential diagnosis Comorbidities Multiple sclerosis Parkinson’s disease Polyneuropathy 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

J. Winkelmann gibt folgende Interessenkonflikte an: Förderungen von DFG, Era Net Neuron, Deutsche RLS-Vereinigung. Honorare von Bayer Vital GmbH, UCB. Weiterhin ein angemeldetes Patent: 17 15 6438.8. B. Högl gibt folgende Interessenkonflikte an: Vortragshonorare von Lundbeck, Lilly, Janssen Cilag, Otsuka, Abbvie, UCB, Mundipharma. Beratung für Axovant, Benevolent Bio und Mundipharma. Reisekostenübernahme von Air Liquide und Habel Medizintechnik, Wien. C. Trenkwalder gibt folgende Interessenkonflikte an: Tätigkeit in Advisory Boards von: Gruenenthal, UCB, Vifor Pharma, Britannia Pharmaceuticals, Benevolent Bio, Novartis. Vortragshonorare von: UCB, Britannia, Mundipharma, Abbvie, Servier. Lizenzgebühren vom: Schattauer Verlaggeben. M. Bartl und W. Paulus geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Allen RP, Chen C, Garcia-Borreguero D et al (2014) Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med 370:621–631CrossRefGoogle Scholar
  2. 2.
    Allen RP, Picchietti DL, Garcia-Borreguero D et al (2014) Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria – history, rationale, description, and significance. Sleep Med 15:860–873CrossRefGoogle Scholar
  3. 3.
    Angelini M, Negrotti A, Marchesi E et al (2011) A study of the prevalence of restless legs syndrome in previously untreated Parkinson’s disease patients: absence of co-morbid association. J Neurol Sci 310:286–288CrossRefGoogle Scholar
  4. 4.
    Association AP (2013) Diagnostic and statistical manual of mental disorders : DSM-5, 5. Aufl. American Psychiatric Association, VirginaCrossRefGoogle Scholar
  5. 5.
    Aydar G, Kurt S, Karaer Unaldi H, Erkorkmaz U (2011) Restless legs syndrome in multiple sclerosis. Eur Neurol 65(5):302–306CrossRefGoogle Scholar
  6. 6.
    Bachmann CG, Rolke R, Scheidt U et al (2010) Thermal hypoaesthesia differentiates secondary restless legs syndrome associated with small fibre neuropathy from primary restless legs syndrome. Brain 133:762–770CrossRefGoogle Scholar
  7. 7.
    Bastia JK, Bhoi SK, Kalita J et al (2015) Neuropathy in a cohort of restless leg syndrome patients. J Clin Neurosci 22:1314–1318CrossRefGoogle Scholar
  8. 8.
    Bhalsing K, Suresh K, Muthane UB et al (2013) Prevalence and profile of restless legs syndrome in parkinson’s disease and other neurodegenerative disorders: a case-control study. Parkinsonism Relat Disord 19:426–430CrossRefGoogle Scholar
  9. 9.
    Bruno E, Nicoletti A, Messina S et al (2015) Restless legs syndrome and multiple sclerosis: a population based case-control study in Catania, Sicily. Eur J Neurol 22:1018–1021CrossRefGoogle Scholar
  10. 10.
    Earley CJ, Connor J, Garcia-Borreguero D et al (2014) Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease). Sleep Med 15:1288–1301CrossRefGoogle Scholar
  11. 11.
    Ferini-Strambi L, Walters AS, Sica D (2014) The relationship among restless legs syndrome (Willis-Ekbom Disease), hypertension, cardiovascular disease, and cerebrovascular disease. J Neurol 261:1051–1068CrossRefGoogle Scholar
  12. 12.
    Gjerstad MD, Tysnes OB, Larsen JP (2011) Increased risk of leg motor restlessness but not RLS in early Parkinson disease. Neurology 77:1941–1946CrossRefGoogle Scholar
  13. 13.
    Gomez-Choco MJ, Iranzo A, Blanco Y, Graus F, Santamaria J, Saiz A (2007) Prevalence of restless legs syndrome and REM sleep behavior disorder in multiple sclerosis. MultScler 13(6):805–808Google Scholar
  14. 14.
    Hattan E, Chalk C, Postuma RB (2009) Is there a higher risk of restless legs syndrome in peripheral neuropathy? Neurology 72:955–960CrossRefGoogle Scholar
  15. 15.
    Hening WA, Allen RP, Washburn M et al (2009) The four diagnostic criteria for Restless Legs Syndrome are unable to exclude confounding conditions („mimics“). Sleep Med 10:976–981CrossRefGoogle Scholar
  16. 16.
    Hogl B, Stefani A, Videnovic A (2018) Idiopathic REM sleep behaviour disorder and neurodegeneration – an update. Nat Rev Neurol 14:40–55CrossRefGoogle Scholar
  17. 17.
    Holbech JV, Bach FW, Finnerup NB et al (2016) Pain phenotype as a predictor for drug response in painful polyneuropathy – a retrospective analysis of data from controlled clinical trials. Pain 157:1305–1313CrossRefGoogle Scholar
  18. 18.
    Italian RSG, Manconi M, Ferini-Strambi L et al (2008) Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep 31:944–952CrossRefGoogle Scholar
  19. 19.
    Krishnan PR, Bhatia M, Behari M (2003) Restless legs syndrome in Parkinson’s disease: a case-controlled study. Mov Disord 18:181–185CrossRefGoogle Scholar
  20. 20.
    Li Y, Munger KL, Batool-Anwar S et al (2012) Association of multiple sclerosis with restless legs syndrome and other sleep disorders in women. Neurology 78:1500–1506CrossRefGoogle Scholar
  21. 21.
    Liu G, Feng X, Lan C et al (2015) Restless leg syndrome and multiple sclerosis: a case-control study in China. Sleep Breath 19:1355–1360CrossRefGoogle Scholar
  22. 22.
    Loo HV, Tan EK (2008) Case-control study of restless legs syndrome and quality of sleep in Parkinson’s disease. J Neurol Sci 266:145–149CrossRefGoogle Scholar
  23. 23.
    Marchesi E, Negrotti A, Angelini M et al (2016) A prospective study of the cumulative incidence and course of restless legs syndrome in de novo patients with Parkinson’s disease during chronic dopaminergic therapy. J Neurol 263:441–447CrossRefGoogle Scholar
  24. 24.
    Mery V, Kimoff RJ, Suarez I et al (2015) High false-positive rate of questionnaire-based restless legs syndrome diagnosis in multiple sclerosis. Sleep Med 16:877–882CrossRefGoogle Scholar
  25. 25.
    Minar M, Petrlenicova D, Valkovic P (2017) Higher prevalence of restless legs syndrome/Willis-Ekbom disease in multiple sclerosis patients is related to spinal cord lesions. Mult Scler Relat Disord 12:54–58CrossRefGoogle Scholar
  26. 26.
    Moccia M, Erro R, Picillo M et al (2016) A four-year longitudinal study on restless legs syndrome in Parkinson disease. Sleep 39:405–412CrossRefGoogle Scholar
  27. 27.
    Muntean M‑L, Sixel-Döring F, Trenkwalder C (2015) Serum Ferritin levels in Parkinson’s disease patients with and without restless legs syndrome. Mov Disord Clin Pract 2:249–252CrossRefGoogle Scholar
  28. 28.
    Nineb A, Rosso C, Dumurgier J et al (2007) Restless legs syndrome is frequently overlooked in patients being evaluated for polyneuropathies. Eur J Neurol 14:788–792CrossRefGoogle Scholar
  29. 29.
    Nomura T, Inoue Y, Miyake M, Yasui K, Nakashima K (2006) Prevalence and clinical characteristics of restless legs syndrome in Japanese patients with Parkinson’s disease. Mov Disord 21(3):380–384CrossRefGoogle Scholar
  30. 30.
    Piao YS, Lian TH, Hu Y et al (2017) Restless legs syndrome in Parkinson disease: clinical characteristics, abnormal iron metabolism and altered neurotransmitters. Sci Rep 7:10547CrossRefGoogle Scholar
  31. 31.
    Rajabally YA, Martey J (2013) No association between neuropathy and restless legs in Parkinson’s disease. Acta Neurol Scand 127:216–220CrossRefGoogle Scholar
  32. 32.
    Rana AQ, Siddiqui I, Mosabbir A et al (2013) Association of pain, Parkinson’s disease, and restless legs syndrome. J Neurol Sci 327:32–34CrossRefGoogle Scholar
  33. 33.
    Rana AQ, Mosabbir AA, Qureshi AR et al (2016) Restless leg syndrome: a risk factor of higher prevalence of anxiety and depression in Parkinson’s disease patients. Neurol Res 38:309–312CrossRefGoogle Scholar
  34. 34.
    Rana AQ et al (2016) Association of restless legs syndrome, pain, and mood disorders in Parkinson’s disease. Int J Neurosci 126(2):116–120CrossRefGoogle Scholar
  35. 35.
    Schormair B, Plag J, Kaffe M et al (2011) MEIS1 and BTBD9: genetic association with restless leg syndrome in end stage renal disease. J Med Genet 48:462–466CrossRefGoogle Scholar
  36. 36.
    Schormair B, Zhao C, Bell S et al (2017) Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. Lancet Neurol 16:898–907CrossRefGoogle Scholar
  37. 37.
    Schulte EC, Knauf F, Kemlink D et al (2011) Variant screening of the coding regions of MEIS1 in patients with restless legs syndrome. Neurology 76:1106–1108CrossRefGoogle Scholar
  38. 38.
    Schulte EC, Kousi M, Tan PL et al (2014) Targeted resequencing and systematic in vivo functional testing identifies rare variants in MEIS1 as significant contributors to restless legs syndrome. Am J Hum Genet 95:85–95CrossRefGoogle Scholar
  39. 39.
    Shah RS, Rajabally YA (2013) Restless legs syndrome in sensory axonal neuropathy: a case-control study. Rev Neurol (Paris) 169:228–233CrossRefGoogle Scholar
  40. 40.
    Sorgun MH, Aksun Z, Atalay YB et al (2015) Restless legs syndrome in multiple sclerosis. Turk J Med Sci 45:1268–1273CrossRefGoogle Scholar
  41. 41.
    Stefansson H, Rye DB, Hicks A et al (2007) A genetic risk factor for periodic limb movements in sleep. N Engl J Med 357:639–647CrossRefGoogle Scholar
  42. 42.
    Suzuki K, Okuma Y, Uchiyama T et al (2017) Characterizing restless legs syndrome and leg motor restlessness in patients with Parkinson’s disease: A multicenter case-controlled study. Parkinsonism Relat Disord 44:18–22CrossRefGoogle Scholar
  43. 43.
    Szatmari S Jr., Bereczki D, Fornadi K et al (2017) Association of restless legs syndrome with incident Parkinson’s disease. Sleep40(2).  https://doi.org/10.1093/sleep/zsw065 CrossRefPubMedGoogle Scholar
  44. 44.
    Szentkiralyi A, Volzke H, Hoffmann W et al (2014) Multimorbidity and the risk of restless legs syndrome in 2 prospective cohort studies. Neurology 82:2026–2033CrossRefGoogle Scholar
  45. 45.
    Teodoro T, Viana P, Abreu D et al (2015) A peripheral pathway to restless legs syndrome? Clues from familial amyloid polyneuropathy. Parkinsonism Relat Disord 21:1465–1468CrossRefGoogle Scholar
  46. 46.
    Tinelli MJJ, Dauvilliers Y, Ferri R, Rijsman R, Sakkas GK, Trenkwalder C, Oertel W (2017) Socio economic impact of RLS & inadequate RLS treatment across different healthcare systems. European Brain CouncilGoogle Scholar
  47. 47.
    Trenkwalder C, Allen R, Hogl B et al (2016) Restless legs syndrome associated with major diseases: a systematic review and new concept. Neurology 86:1336–1343CrossRefGoogle Scholar
  48. 48.
    Trenkwalder C, Paulus W (2010) Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol 6:337–346CrossRefGoogle Scholar
  49. 49.
    Vavrova J, Kemlink D, Sonka K et al (2012) Restless legs syndrome in Czech patients with multiple sclerosis: an epidemiological and genetic study. Sleep Med 13(7):848–851CrossRefGoogle Scholar
  50. 50.
    Vilarino-Guell C, Chai H, Keeling BH et al (2009) MEIS1 p.R272H in familial restless legs syndrome. Neurology 73:243–245CrossRefGoogle Scholar
  51. 51.
    Winkelmann J, Czamara D, Schormair B et al (2011) Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. PLoS Genet 7:e1002171CrossRefGoogle Scholar
  52. 52.
    Winkelmann J, Schormair B, Xiong L et al (2017) Genetics of restless legs syndrome. Sleep Med 31:18–22CrossRefGoogle Scholar
  53. 53.
    You HJ, Lei J, Arendt-Nielsen L (2009) Selective inhibitory effects of pregabalin on peripheral C but not A‑delta fibers mediated nociception in intact and spinalized rats. Neuroscience 164:1845–1853CrossRefGoogle Scholar
  54. 54.
    Zhu XY, Liu Y, Zhang XJ, Yang WH, Feng Y, Ondo WG et al (2015) Clinical characteristics of leg restlessness in Parkinson’s disease compared with idiopathic Restless Legs Syndrome. Journal of the neurological sciences. J Neurol Sci 357:109–114Google Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • M. Bartl
    • 1
  • J. Winkelmann
    • 2
    • 6
    • 7
  • B. Högl
    • 3
  • W. Paulus
    • 1
  • C. Trenkwalder
    • 4
    • 5
  1. 1.Klinik für Klinische NeurophysiologieUniversitätsmedizin GöttingenGöttingenDeutschland
  2. 2.Institut für Neurogenomik Helmholtz Zentrum MünchenNeuherbergDeutschland
  3. 3.Universitätsklinik für NeurologieMedizinische Universität InnsbruckInnsbruckÖsterreich
  4. 4.Zentrum für Parkinson-Syndrome und BewegungsstörungenParacelsus-Elena KlinikKasselDeutschland
  5. 5.Klinik für NeurochirurgieUniversitätsmedizin GöttingenGöttingenDeutschland
  6. 6.Neurologische Klinik und Poliklinik, Klinikum rechts der IsarTechnische Universität MünchenMünchenDeutschland
  7. 7.Munich Cluster for Systems Neurology (SyNergy)MünchenDeutschland

Personalised recommendations